Please assess the completion status of the following clinical trial:

Trial Title: Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* All patients receiving a T cell depleted BMT from a mismatched family member or unrelated donor will be eligible for this protocol. In addition, patients receiving a matched sibling transplant or T replete transplant may be eligible if they are at high risk of developing EBV LPD because of their underlying disease (e.g Wiskott-Aldrich or Ataxia Telangiectasia) or have a past history of EBVLPD or other EBV associated malignancy.~* O2 saturation \> 90% on room air~EXCLUSION CRITERIA:~- Exclusion criteria for BMT will be as detailed in the relevant protocol.~Exclusion criteria at time of administration CTLs:~* Patients with GVHD of Grade II or greater.~* Patients with severe renal disease (i.e., creatinine clearance less than half normal for age).~* Patients with severe hepatic disease (bilirubin greater than twice normal, or SGOT greater than 3 x normal).~* Patients with a severe intercurrent infection.~* Patients with a life expectancy \<6 weeks

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EBV specific T cells (Type: EXPERIMENTAL): EBV specific T cells

Based on this trial design, predict the completion outcome and termination type (if applicable).